Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Albright

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
ACS Medicinal Chemistry Letters|March 21, 2019
Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481Kenneth M Boy, Jason M Guernon, Dmitry S Zuev, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 19, 2016
Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human SubjectsJeremy H Toyn, Kenneth M Boy, Joseph Raybon, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 2013
Pharmacodynamics of selective inhibition of γ-secretase by avagacestatCharles F Albright, Randy C Dockens, Jere E Meredith, et al.
The Journal of Biological Chemistry|June 25, 2008
The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expressionCatherine R Burton, Jere E Meredith, Donna M Barten, et al.
Nature Medicine|January 22, 2019
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10Morgan L Maeder, Michael Stefanidakis, Christopher J Wilson, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathiesAmy Easton, Marianne L Jensen, Congwei Wang, et al.
Journal of Medicinal Chemistry|March 9, 2022
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic PainGuanglin Luo, Ling Chen, Walter A Kostich, et al.
International Journal of Alzheimer'S Disease|August 7, 2014
Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780Jeremy H Toyn, Lorin A Thompson, Kimberley A Lentz, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 29, 2017
Preclinical Characterization of (<i>R</i>)-3-((3<i>S</i>,4<i>S</i>)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate <i>N</i>-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive DisorderLinda J Bristow, Jyoti Gulia, Michael R Weed, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 15, 2016
Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic PainWalter Kostich, Brian D Hamman, Yu-Wen Li, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
ACS Medicinal Chemistry Letters|March 21, 2019
Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481Kenneth M Boy, Jason M Guernon, Dmitry S Zuev, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 19, 2016
Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human SubjectsJeremy H Toyn, Kenneth M Boy, Joseph Raybon, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 2013
Pharmacodynamics of selective inhibition of γ-secretase by avagacestatCharles F Albright, Randy C Dockens, Jere E Meredith, et al.
The Journal of Biological Chemistry|June 25, 2008
The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expressionCatherine R Burton, Jere E Meredith, Donna M Barten, et al.
Nature Medicine|January 22, 2019
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10Morgan L Maeder, Michael Stefanidakis, Christopher J Wilson, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathiesAmy Easton, Marianne L Jensen, Congwei Wang, et al.
Journal of Medicinal Chemistry|March 9, 2022
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic PainGuanglin Luo, Ling Chen, Walter A Kostich, et al.
International Journal of Alzheimer'S Disease|August 7, 2014
Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780Jeremy H Toyn, Lorin A Thompson, Kimberley A Lentz, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 29, 2017
Preclinical Characterization of (<i>R</i>)-3-((3<i>S</i>,4<i>S</i>)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate <i>N</i>-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive DisorderLinda J Bristow, Jyoti Gulia, Michael R Weed, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 15, 2016
Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic PainWalter Kostich, Brian D Hamman, Yu-Wen Li, et al.
Pageof 14